Arrowhead Pharmaceuticals Corp (ARWR) Q4 Revs Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Arrowhead Pharmaceuticals Corp (ARWR) May Be Worth $75-$90 in a Sale - Cantor Fitzgerald
November 26, 2019 1:44 PM ESTCantor Fitzgerald analyst Alethia Young said Arrowhead Pharmaceuticals Corp (NASDAQ: ARWR) may be worth $75-$90 in a sale. The analyst reiterated a Neutral rating and $50 price target.
... More